Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2
/PRNewswire/ -- Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an...
Source: prnewswire.com